What's Happening?
GeneDx, a leader in rare disease diagnosis, announced it will launch 'Easy Order' at the 2026 American Academy of Pediatrics (AAP) National Conference & Exhibition in San Diego. This new streamlined system aims to simplify the process for general pediatricians
to order ExomeDx™ and chromosomal microarray (CMA) tests. The initiative follows the AAP's 2025 guidance recommending exome or genome sequencing as a first-tier test for children with global developmental delay (GDD) or intellectual disability (ID). GeneDx's goal is to remove barriers to genomic testing, making it more accessible for pediatricians who may not regularly order such tests. The 'Easy Order' system, available through the GeneDx Provider Portal, features a guided workflow to reduce required inputs and ensure complete orders. Additionally, GeneDx is developing Provider Report Guides to offer pediatrician-friendly explanations within reports, helping non-genetics experts interpret results, communicate them to families, and determine next steps. These efforts are part of a broader strategy to integrate genomic testing into routine pediatric care.
Why It's Important?
The introduction of 'Easy Order' by GeneDx is significant for U.S. pediatric healthcare, particularly in the diagnosis of rare diseases and neurodevelopmental conditions. By simplifying genomic testing, GeneDx aims to empower general pediatricians, who are often the first to identify developmental concerns, to provide earlier and more precise diagnoses. This shift aligns with the AAP's updated recommendations, potentially reducing diagnostic delays and misdiagnoses that families often experience. Earlier diagnosis can lead to more personalized care and connect families with condition-specific resources and support sooner. The initiative also addresses the challenge of integrating complex genomic data into routine practice by offering educational resources and simplified reporting, thereby bridging the knowledge gap for non-genetics experts. This could lead to improved health outcomes for children with GDD or ID by facilitating timely interventions and management strategies.
What's Next?
GeneDx will officially introduce 'Easy Order' at the 2026 American Academy of Pediatrics National Conference & Exhibition, scheduled for October 2-6 in San Diego. During the conference, GeneDx will host educational programming focused on integrating exome and genome sequencing into pediatric care. This includes a practical guide for pediatricians on implementing recommended genetic testing for patients with GDD or ID, and a session on the benefits of earlier genetic testing in pediatric care. The company will continue to develop Provider Report Guides and educational resources to support pediatricians in interpreting and communicating genetic findings. GeneDx is also serving as an implementation partner for the Leveraging Genomic Assessment of Developmental Delay (LEAD) Project, a national initiative aimed at advancing earlier genomic testing for children with developmental delay and related neurodevelopmental conditions.
Beyond the Headlines
The broader implications of GeneDx's 'Easy Order' extend to the evolving landscape of precision medicine in the U.S. The move signifies a growing trend towards democratizing access to advanced genomic technologies, moving them from specialized genetics clinics into the hands of general practitioners. This could raise important questions about the training and support required for a wider range of healthcare providers to effectively utilize and interpret genomic data. Furthermore, as genomic testing becomes more routine, there will be an increased need for robust genetic counseling infrastructure to help families understand complex results, particularly those with uncertain clinical significance or implications for future disease onset. The initiative also highlights the potential for AI-driven genomic intelligence, as GeneDx Infinity™ fuels discovery for biopharma, suggesting a future where genomic data not only aids diagnosis but also accelerates therapeutic development for rare diseases.













